Acute Ocular Pain Market

DelveInsight’s ‘Acute Ocular Pain (AOP)—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the AOP, historical and forecasted epidemiology as well as the AOP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and Canada.

The AOP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM, China, and Canada AOP market size from 2018 to 2030. The Report also covers current AOP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China
• Canada

Study Period: 2018–2030

Acute Ocular Pain (AOP) Disease Understanding and Treatment Algorithm

Acute Ocular Pain (AOP) Overview

Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from straightforward refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any structures around the eye or referred pain from tissues with similar innervation as ocular tissues (V1). Patients with eye pain or periorbital pain frequently present to primary care physicians, neurologists, or ophthalmologists.

Most ophthalmologic conditions producing ocular pains are associated with obvious ocular symptoms and signs like red-eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet eye or “white eye”.

Depending on where the patients experience the discomfort, eye pain can fall into one of two categories: Ocular pain occurring on the eye’s surface and orbital pain within the eye.

Eye pain that occurs on the surface may be scratching, burning, or itching sensation. Surface pain is usually caused by irritation from a foreign object, infection, or trauma. Often, this type of eye pain is easily treated with eye drops or rest.

Continued in the report…..

Acute Ocular Pain (AOP) Diagnosis

History

The initial evaluation should include questions about vision loss or changes. Eye pain with vision loss requires immediate ophthalmology referral.

A foreign body sensation suggests a corneal process, such as a corneal abrasion, retained foreign body, or keratitis. In contrast, a scratchy, gritty, or sandy sensation is more likely to be associated with conjunctivitis.

When assessing for keratitis, clinicians should ask about contact lens use and discuss lens care regimens. A contact lens history includes wearing schedule, overnight wear, contact lens hygiene protocol, use of tap water to rinse contact lenses, and swimming, using a hot tub, or showering while wearing contact lenses. Bacterial and Acanthamoeba keratitis is associated with inappropriate contact lens use or care.

Physical Examination

Vital signs are checked for the presence of fever. The nose is inspected for purulent rhinorrhea, and the face is palpated for tenderness. If the eye is red, the preauricular region is checked for adenopathy. Hygiene during the examination must be scrupulous when examining patients who have chemosis, preauricular adenopathy, punctate corneal staining, or a combination; these findings suggest epidemic keratoconjunctivitis, which is highly contagious.

The eye examination should be as complete as possible for patients with eye pain. Best-corrected visual acuity is checked. Visual fields are typically tested by confrontation in patients with eye pain, but this test can be insensitive (particularly for small defects) and unreliable because of poor patient cooperation. A light is moved from one eye to the other to check for pupillary size and direct and consensual pupillary light responses. In patients who have unilateral eye pain, a light is shined in the unaffected eye while the affected eye is shut; pain in the affected eye represents true photophobia. Extraocular movements are checked. The orbital and periorbital structures are inspected. A conjunctival injection that seems most intense and confluent around the cornea and limbus is called a ciliary flush.

Testing

Testing is not usually necessary, with some exceptions. Gonioscopy is done if glaucoma is suspected based on increased intraocular pressure. Imaging, usually with CT or MRI, is done if orbital pseudotumor or orbital cellulitis is suspected or if sinusitis is suspected, but the diagnosis is not clinically apparent. MRI is often done when optic neuritis is suspected, looking for demyelinating lesions in the brain suggesting multiple sclerosis.

Continued in the report…..

Acute Ocular Pain (AOP) Treatment

Approaches to the treatment of ocular pain come from the fields of neuroscience, neurology, and pain management rather than the field of ophthalmology. Clinicians should be alert and attuned to the possibility that a patient might have a pain syndrome rather than a report of physiologic nociception. Symptoms are, of course, the manifestation of signaling and should be the focus of treatment. Continued signaling converts peripheral to centralized pain and acute to chronic pain. The goal of treatment is to reduce signaling. This might seem obvious since the patient is seeks treatment for symptoms, but when it is recognized that the syndrome is pathologic pain rather than underlying organ or tissue disease, one is more likely to pick therapies geared directly to reducing signaling.

People with ocular pain typically present or are referred to ophthalmologists or optometrists for evaluation. When there is recent trauma or surgery, or signs of an infectious or inflammatory process, treatment of the underlying process or pathologic abnormality usually results in resolution of pain. These situations represent physiologic or nociceptive pain. Such pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.

Continued in the report…..

Acute Ocular Pain (AOP) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Several Eye Disorders, and Total Cases of Acute Ocular Pain (AOP) scenario in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and Canada from 2018 to 2030.

Key Findings

• In 2020, the total cases of Acute Ocular Pain (AOP) were 27,327,387 cases in the 7MM, Canada and China, which might increase by 2030.
• In 2020 the US accounted for 4,038,628 AOP cases, which is anticipated to increase by 2030.
• In 2020, the EU5 countries accounted for 4,527,206 cases, which is seen to increase by 2030.
• Among EU5 countries, Germany had the highest number of cases of Acute Ocular Pain (AOP), which were 1,109,517 cases in 2020. As per DelveInsight’s estimates, this count will increase through the study period.
• Japan, in 2020, accounted for 1,315,445 cases of AOP, which will increase by the year 2030.
• In 2020, there were 888,810 cases recorded for AOP in Canada which are estimated to increase during the study period.
• There were 16,557,297 cases recorded for AOP in China during 2020.

Country-Wise Acute Ocular Pain (AOP) Epidemiology

The epidemiology segment also provides the AOP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and Canada.

Acute Ocular Pain (AOP) Drug Chapters

Acute Ocular Pain (AOP) Marketed Drugs

Dextenza (dexamethasone ophthalmic insert): Ocular Therapeutix

Dextenza is contraindicated in patients with active corneal, conjunctival, or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, fungal diseases of the eye, and dacryocystitis. Dextenza is inserted in the lower lacrimal punctum and into the canaliculus. A single Dextenza releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. Dextenza is resorbable and does not require removal.

Although the drug is already approved in adults, currently it is in Phase III clinical trial for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.

Products detail in the report…

Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals

Inveltys (loteprednol etabonate/KPI-121) is a nanoparticle ocular corticosteroid formulation for the treatment of postoperative ocular inflammation and pain. Inveltys, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Products detail in the report…

List to be continued in the report…

AOP Emerging Drugs

APP13007: Formosa Pharmaceuticals

APP13007 is a nanoparticle formulation of the corticosteroid clobetasol in development for the treatment of post-operative inflammation of the eye. Activus was originally developing APP13007 by applying its patented proprietary APNT (Activus Pure Nanoparticle Technology) to the corticosteroid clobetasol propionate to create a novel nanoparticle formulation for treating post-operative inflammation of the eye. Response rate strongly suggests APP13007 outperforms competitors in reducing inflammation and pain for critical Phase III endpoints.

Products detail in the report…

SURF-201: Surface Ophthalmics

SURF-201 is 0.2% betamethasone, a unique and potent corticosteroid formulated as a solution in Surface’s patented Klarity vehicle and is intended to provide improved efficacy and safety when compared to currently used corticosteroids. SURF-201 marks the first ophthalmic therapeutic in the United States to utilize betamethasone, as well as being the first preservative-free unit dose therapy for the treatment of post-operative pain and inflammation. Recently, a Phase II clinical study was completed by the company.

Products detail in the report…

List to be continued in the report…

Acute Ocular Pain (AOP) Market Outlook

Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from very simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any structures around the eye or referred pain from tissues with similar innervation as ocular tissues. Most ophthalmologic conditions producing ocular pains are associated with obvious ocular symptoms and signs like red-eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet eye or “white eye.”

Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.

Continued in the report…..

Key Findings

• Overall Acute Ocular Pain (AOP) market in the 7MM, Canada, and China is expected to reach USD 906 million by 2030.
• The market size in the EU5 is expected to increase to USD 153.6 million by 2030 due to the rising awareness of the disease and launch of the emerging therapies.
• Dextenza, Inveltys, and Lotemax SM—already approved in the US market—are expected to enter the European and Japan market in 2023, 2023, and 2024, respectively.
• The United States is expected to capture the largest market share of AOP by 2030 with USD 487.7 million. Least market share will be captured by Canada with USD 13.8 million in 2030.
• As per the analysis, in China, the total market of AOP stood at USD 68.4 million in 2018 whereas in Canada it was of USD 4.2 million in the same year.

The United States Market Outlook

This section provides the total AOP market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total AOP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total AOP market size and market size by therapies in Japan are provided.

China Market Outlook

In this section, overall market size and market size by therapies for AOP in China is provided in this section.

Canada Market Outlook

Total market size AOP and market size by therapies for AOP in Canada is discussed in this section.

Acute Ocular Pain (AOP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the AOP market or expected to get launched in the market during the study period 2018–2030. The analysis covers the AOP market uptake by drugs; patient uptake by therapies; and sales of each drug.  

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Ocular Pain (AOP) Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for AOP emerging therapies.

Reimbursement Scenario in Acute Ocular Pain (AOP)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the AOP market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

• The report covers the descriptive overview of AOP, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the AOP epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for AOP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the AOP market; historical and forecasted is included in the report, covering the 7MM, China, and Canada drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM, China, and Canada AOP market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the AOP market.
• The companies and academics are working to assess challenges and seek opportunities that could influence AOP R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for AOP. The launch of emerging therapies will significantly impact the AOP market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

AOP Report Insights

• Patient Population
• Therapeutic Approaches
• AOP Pipeline Analysis
• AOP Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

AOP Report Key Strengths

• 10 Years Forecast
• 7MM, China, and Canada Coverage
• AOP Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

AOP Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:

• What was the AOP market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the AOP total market size as well as market size by therapies across the 7MM, China, and Canada during the forecast period (2021–2030)?
• What are the key findings pertaining to the market across the 7MM, China, and Canada and which country will have the largest AOP market size during the forecast period (2021–2030)?
• At what CAGR, the AOP market is expected to grow at the 7MM, China, and Canada level during the forecast period (2021–2030)?
• What would be the AOP market outlook across the 7MM, China, and Canada during the forecast period (2021–2030)?
• What would be the AOP market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of AOP?
• What is the historical AOP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, China, and Canada?
• What would be the forecasted patient pool of AOP at the 7MM, China, and Canada level?
• What will be the growth opportunities across the 7MM, China, and Canada with respect to the patient population pertaining to AOP?
• Out of the above-mentioned countries, which country would have the highest incident population of AOP during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM, China, and Canada during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of AOP along with the approved therapy?
• What are the current treatment guidelines for the treatment of AOP in the US and Europe?
• What are the AOP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of AOP?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of AOP?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AOP therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for AOP and their status?
• What are the key designations that have been granted for the emerging therapies for AOP?
• What are the 7MM, China, and Canada historical and forecasted market of AOP?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving AOP.
• To understand the future market competition in the AOP market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for AOP in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, and Canada.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the AOP market.
• To understand the future market competition in the AOP market.